Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

DNLI - Denali Therapeutics Inc. Последние новости | Finranks

Home

/

DNLI

D

Denali Therapeutics Inc. (DNLI)

NMS – Цена в реальном времени. Валюта: USD

25.17

+0.48 (1.94%)

Рынок открыт: Aug 12, 2026, 12:54 PM EDT

24.65

-0.04 (-0.16%)

Предыдущая сессия: Aug 11, 2026, 7:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics Q2 Earnings Call Highlights

Denali Therapeutics Q2 Earnings Call Highlights

Denali Therapeutics NASDAQ: DNLI reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expanded payer access and advanced two Alzheimer's disease programs into clinical development.

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.72 per share a year ago.

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue Advanced TransportVehicle™ portfolio with two Alzheimer's disease programs now in clinical development $195 million in gross proceeds received in July 2026 from sale of a Priority Review Voucher, bringing pro forma cash, cash equivalents and marketable securities to more than $1.1 billion Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Видео

No Data

There is no data to display

Пресс-релизы

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue Advanced TransportVehicle™ portfolio with two Alzheimer's disease programs now in clinical development $195 million in gross proceeds received in July 2026 from sale of a Priority Review Voucher, bringing pro forma cash, cash equivalents and marketable securities to more than $1.1 billion Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.